Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Trofosfamide metabolism in different species-ifosfamide is the predominant metabolite

  • 41 Accesses

  • 36 Citations


Trofosfamide (TRO) belongs to the group of oxazaphosphorines and is a congener of cyclophosphamide (CYC) and ifosfamide (IFO). The precondition for the cytotoxic effect of all oxazaphosphorines is their metabolic activation by “ring” oxidation at the hepatic mixed-function oxidase system. In addition, an inactivating metabolic pathway (“side chain” oxidation) is known for CYC and IFO. The metabolic pattern of the substances gains special interest in the discussion of a growing incidence of side effects. Therefore, the in vitro biotransformation of TRO was studied. Liver microsomes were prepared from different species, including the rat, rabbit, and mouse as well as from one human sample. Microsomal proteins were incubated for various periods and concentrations of TRO and its metabolites were analyzed by reversed-phase high-performance liquid chromatography (HPLC). In vitro metabolism resulted in the formation of activated metabolites by hydroxylation at position 4. In addition, side-chain oxidation resulted in the formation of IFO and CYC. IFO was the predominating metabolite of this pathway, with a 5- to 6-fold excess being noted as compared with CYC in rats and mice. The rabbit species showed similar CYC and IFO formation; in the single human sample, only IFO could be detected. In rats, the Michaelis constant (Km) for biotransformation to IFO was 398 μM, with the maximal volume (Vmax) being 70.8 nmol 120 min−1 mg protein−1, the corresponding values for biotransformation to CYC were 348 μM and 13.30 nmol 120 min−1 mg protein−1. On the basis of its structural similarity and the current knowledge of oxazaphosphorine metabolism, CYC was expected to be the main metabolite of TRO. The predominance of IFO was unexpected, but the observed metabolic profile promises numerous interesting aspects for the clinical use of TRO.

This is a preview of subscription content, log in to check access.


  1. 1.

    Alacorn RA (1969) Fluorimetric determination of acrolein and related compounds withm-aminophenol. Anal Chem 40: 1704–1708

  2. 2.

    Albrecht M, Kleinkauf-Houken A, Trams G, Thomsen K (1984) 5jährige Erfahrungen mit adjuvanter Chemotherapie beim primären Mammakarzinom. Geburtshilfe Frauenheilkd 44: 550–556

  3. 3.

    Blaschke G, Koch U (1986) Untersuchungen zum stereoselektiven Metabolismus von Ifosfamid. Arch Pharm 319: 1052

  4. 4.

    Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254

  5. 5.

    Boos J, Welslau U, Ritter J, Blaschke G, Schellong G (1991) Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children. Cancer Chemother Pharmacol 28: 455–460

  6. 6.

    Connors TA, Cox PJ, Farmer PB, Foster AB, Jarman M (1974) Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem Pharmacol 23: 115–129

  7. 7.

    Falkson G, Falkson HC (1978) Trofosfamide in the treatment of patients with cancer — a pilot trial. S Afr Med J 53: 886–888

  8. 8.

    Goren MP, Wright RK, Pratt CB, Pell FE (1986) Dechlorethylation of ifosfamide and neurotoxicity. Lancet II: 1219–1220

  9. 9.

    Hohorst HJ, Peter G, Struck RF (1976) Synthesis of 4-hydroperoxy derivatives of ifosfamide and trofosfamide by direct ozonation and preliminary antitumor evaluation in vivo. Cancer Res 36: 2278–2281

  10. 10.

    Kurowski V, Cerny T, Küpfer A, Wagner T (1991) Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J Cancer Res Clin Oncol 117 [Suppl 4]: 148–153

  11. 11.

    Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM (1989) Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res 49: 753–757

  12. 12.

    Norpoth K (1976) Studies on the metabolism of isophosphamide (NSC-109724) in man. Cancer Treat Rep 60: 437–443

  13. 13.

    Norpoth K, Addicks HW, Witting U, Müller G, Raidt H (1975) Quantitative Bestimmung von Cyclophosphamid, Ifosfamid und Trofosfamid sowie ihrer stabilen Metabolite auf der DC-Platte mit 4-Pyridinaldehyd-2-benzothiazolylhydrazon (PHB). Drug Res 25: 1331–1336

  14. 14.

    Omura T, Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 239: 2370–2385

  15. 15.

    Wagner T, Drings P (1986) Pharmacokinetics and bioavailability of oral ifosfamide. Drug Res 36: 878–880

  16. 16.

    Wist E, Risberg T (1991) Trofosfamide in non-Hodgkin's lymphoma — a phase II study. Acta Oncol 30: 819–821

Download references

Author information

Correspondence to J. Boos.

Additional information

One of the authors (F.K) did most of the work as part of his PhD thesis

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Boos, J., Küpker, F., Blaschke, G. et al. Trofosfamide metabolism in different species-ifosfamide is the predominant metabolite. Cancer Chemother. Pharmacol. 33, 71–76 (1993). https://doi.org/10.1007/BF00686026

Download citation


  • Cyclophosphamide
  • Metabolic Profile
  • Liver Microsome
  • Ifosfamide
  • Human Sample